The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force

Dubé, Catherine; Rostom, Alaa; Lewin, Gabriela; Tsertsvadze, Alexander; Barrowman, Nicholas; Code, Catherine; Sampson, Margaret; Moher, David

doi:10.7326/0003-4819-146-5-200703060-00009

Cited by 301 publications

(231 citation statements)

References 53 publications

Supporting

Mentioning

218

Contrasting

Unclassified

Order By: Relevance

“…In Korea among 143 patients with CRC, high VEGF levels demonstrated a significant correlation with a lower survival rate but, there was no relationship between VEGF level and age or sex (Greene, 2002). In our study, no significant difference was found for VEGF level between patients and normal subjects before treatment similar to findings of another study in Lebanon (Greene, 2002) and in Japan (Mandel et al, 2000), but was different to results of other studies in Japan (Pignone et al, 2002) and in Germany (Dube et al, 2007).…”

Section: Discussionsupporting

confidence: 53%

“…In another study in Germany among 122 patients with CRC, VEGF level had a significant correlation with tumor size and patients with VEGF level greater than cut-off point had a poorer prognosis than those patients with VEGF level less than cut-off point (Dube et al, 2007). Another study in Italy among 81 patients with CRC revealed that there was a significant difference between serum VEGF level in patients with CRC and normal healthy group.…”

Section: Discussionmentioning

confidence: 95%

“…(Ahluwalia et al, 2014). As VEGF is expressed in a variety of human tumors, the determination of VEGF serum concentration could be a diagnostic method in cancer patients (Dube et al, 2007). In a multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases, it was demonstrated that the combination detection of CEA, VEGF, and EGFR might be an effective way to predict CRC liver metastasis (Qian et al, 2012) and also for negative expression of VEGF as an important prognostic factor in metastatic colorectal carcinoma (Kara et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Significance of Serum Vascular Endothelial Growth Factor and Complement 3a Levels in Patients with Colorectal Cancer in Southern Iran

Mehrabani

Shamsdin²,

Dehghan³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Colon cancer (CRC) is perhaps the second most common cause of cancer mortality. This study determined the clinical significance of serum vascular endothelial growth factor (VEGF) and serum complement 3a (C3a) levels in patients with CRC in Fars province, southern Iran. Materials and Methods: Between June 2010 and June 2012, 110 patients with CRC of both genders and different age groups were divided into 3 groups. Group A included patients who had just undergone surgery; Group B had undergone chemotherapy after surgery; and Group C had undergone chemotherapy and radiotherapy after surgery. Twenty one healthy subjects with normal colonoscopy were considered as a control group. ELISA was undertaken to determine VEGF and C3a levels before and after treatment measures. Results: The mean age of patients was 53.9±14.1 years. Considering VEGF level, a significant decrease was visible after treatment measures in groups A and B, but not Group C. For VEGF level, the difference was not statistically significant between two genders and various age groups before and after treatment. No significant difference was found for VEGF level between patients and normal group before any treatment. Regarding C3a levels in 101 subjects, they significantly decreased after treatment measures. Before and after treatment, the difference was statistically significant between two genders, but was not statistically significant among various age groups. Conclusions: As VEGF and C3a levels were significantly lower in patients after treatment, these may be beneficial markers in assessment of CRC therapy especially in early stages.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Significance of Serum Vascular Endothelial Growth Factor and Complement 3a Levels in Patients with Colorectal Cancer in Southern Iran

Mehrabani

Shamsdin²,

Dehghan³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The analysis of data showed that regular use of aspirin reduced the incidence of colonic adenomas in randomized controlled trials (RR:0.82, 95%CI:0.7-.0.95) and case-control studies (RR:0.87, 95%CI:0.77-.0.98). In cohort studies, regular use of aspirin was associated with RR reductions of 22% for incidence of colorectal cancer 27 .…”

Section: Obesity and Colorectal Cancermentioning

confidence: 98%

Obesity and Colorectal Cancer

Jochem

Leitzmann

2016

Obesity and Cancer

View full text Add to dashboard Cite

“…A review of aspirin prevention for CRC reported only one death associated with gastrointestinal bleeding. 39 We also did not model increased risk for hemorrhagic stroke in patients taking aspirin. However, any increase in risk for hemorrhagic stroke might be compensated by a risk reduction for ischemic stroke.…”

Section: Limitationsmentioning

confidence: 99%

Economic evaluation of genetic screening for Lynch syndrome in Germany

Severin

Stollenwerk

Holinski‐Feder

et al. 2015

Genetics in Medicine

139

View full text Add to dashboard Cite

Purpose: Lynch syndrome (LS) screening among patients with newly diagnosed colorectal cancer can decrease mortality in their affected first-degree relatives. In Germany, it is not yet clinical practice and the cost-effectiveness of different testing strategies is unknown. Methods:We developed a decision-analytic model to analyze the cost-effectiveness of LS screening from the perspective of the German Statutory Health Insurance system. A total of 22 testing strategies considering family-history assessment, analysis of tumor samples (i.e., immunohistochemistry (IHC), microsatellite instability, and BRAF mutation testing) and genetic sequencing were analyzed. Life-years gained in relatives by closedmeshed colonoscopy and aspirin prophylaxis were estimated by Markov models. Uncertainty was assessed deterministically and probabilistically.Results: On average, detected mutation carriers gained 0.52 lifeyears (undiscounted: 1.34) by increased prevention. Most strategies were dominated, with three exceptions: family assessment by the Bethesda criteria followed by IHC and BRAF testing and genetic sequencing; IHC and BRAF testing and genetic sequencing; and direct sequencing of all index patients. Their incremental cost-effectiveness was €77,268, €253,258, and €4,188,036 per life-year gained, respectively. Conclusion:The results were less favorable than those of previous models. Chemoprevention appears to provide comparably low additional benefit and improves cost-effectiveness only slightly.

show abstract

The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force

Cited by 301 publications

References 53 publications

Clinical Significance of Serum Vascular Endothelial Growth Factor and Complement 3a Levels in Patients with Colorectal Cancer in Southern Iran

Clinical Significance of Serum Vascular Endothelial Growth Factor and Complement 3a Levels in Patients with Colorectal Cancer in Southern Iran

Obesity and Colorectal Cancer

Economic evaluation of genetic screening for Lynch syndrome in Germany

Contact Info

Product

Resources

About